Moleculin Biotech (MBRX)
NASDAQ:MBRX
Total Valuation
Moleculin Biotech has a market cap or net worth of $11.95M. The enterprise value is -$5.81M.
Market Cap$11.95M
Enterprise Value-$5.81M
Share Statistics
Moleculin Biotech has 5,336,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,336,350
Owned by Insiders22.30%
Owned by Institutions<0.01%
Financial Efficiency
Moleculin Biotech’s return on equity (ROE) is -2.24 and return on invested capital (ROIC) is -162.91%.
Return on Equity (ROE)-2.24
Return on Assets (ROA)-1.52
Return on Invested Capital (ROIC)-162.91%
Return on Capital Employed (ROCE)-1.64
Revenue Per Employee0.00
Profits Per Employee-1.97M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Moleculin Biotech is ―. Moleculin Biotech’s PEG ratio is 0.01.
PE Ratio―
PS Ratio0.00
PB Ratio2.61
Price to Fair Value2.61
Price to FCF-1.72
Price to Operating Cash Flow-1.17
PEG Ratio0.01
Income Statement
In the last 12 months, Moleculin Biotech had revenue of 0.00 and earned -33.56M in profits. Earnings per share was -28.42.
Revenue0.00
Gross Profit-90.00K
Operating Income-25.10M
Pretax Income-33.56M
Net Income-33.56M
EBITDA-25.01M
Earnings Per Share (EPS)-28.42
Cash Flow
In the last 12 months, operating cash flow was -22.73M and capital expenditures 0.00, giving a free cash flow of -22.73M billion.
Operating Cash Flow-22.73M
Free Cash Flow-22.73M
Free Cash Flow per Share-4.26
Dividends & Yields
Moleculin Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.50
52-Week Price Change-90.80%
50-Day Moving Average3.22
200-Day Moving Average9.04
Relative Strength Index (RSI)46.91
Average Volume (3m)2.74M
Important Dates
Moleculin Biotech upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Moleculin Biotech as a current ratio of 1.41, with Debt / Equity ratio of 2.39%
Current Ratio1.41
Quick Ratio1.41
Debt to Market Cap<0.01
Net Debt to EBITDA0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Moleculin Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Moleculin Biotech EV to EBITDA ratio is -1.23, with an EV/FCF ratio of -1.35.
EV to Sales0.00
EV to EBITDA-1.23
EV to Free Cash Flow-1.35
EV to Operating Cash Flow-1.35
Balance Sheet
Moleculin Biotech has $8.88M in cash and marketable securities with $359.00K in debt, giving a net cash position of $8.52M billion.
Cash & Marketable Securities$8.88M
Total Debt$359.00K
Net Cash$8.52M
Net Cash Per Share$1.60
Tangible Book Value Per Share$0.33
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Moleculin Biotech is $21.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.00
Price Target Upside837.50% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast79.31%